ZA200708188B - Injectable depot formulations and methods for providing sustained release of nanoparticle compositions - Google Patents

Injectable depot formulations and methods for providing sustained release of nanoparticle compositions

Info

Publication number
ZA200708188B
ZA200708188B ZA200708188A ZA200708188A ZA200708188B ZA 200708188 B ZA200708188 B ZA 200708188B ZA 200708188 A ZA200708188 A ZA 200708188A ZA 200708188 A ZA200708188 A ZA 200708188A ZA 200708188 B ZA200708188 B ZA 200708188B
Authority
ZA
South Africa
Prior art keywords
methods
sustained release
nanoparticle compositions
injectable depot
depot formulations
Prior art date
Application number
ZA200708188A
Other languages
English (en)
Inventor
Shah Jaymin Chandrakant
Shah Parag Suresh
Wagner Dawn Renee
Wisniecki Peter
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ZA200708188B publication Critical patent/ZA200708188B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B1/00—Nanostructures formed by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
ZA200708188A 2005-04-13 2007-09-25 Injectable depot formulations and methods for providing sustained release of nanoparticle compositions ZA200708188B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67112405P 2005-04-13 2005-04-13

Publications (1)

Publication Number Publication Date
ZA200708188B true ZA200708188B (en) 2008-10-29

Family

ID=36602931

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200708188A ZA200708188B (en) 2005-04-13 2007-09-25 Injectable depot formulations and methods for providing sustained release of nanoparticle compositions

Country Status (14)

Country Link
US (1) US20080193542A1 (zh)
EP (1) EP1874268A1 (zh)
JP (1) JP2008538751A (zh)
KR (1) KR20070119678A (zh)
CN (1) CN101166514A (zh)
AU (2) AU2006233345A1 (zh)
BR (1) BRPI0609299A2 (zh)
CA (1) CA2605153A1 (zh)
IL (1) IL186131A0 (zh)
MX (1) MX2007012103A (zh)
NZ (1) NZ561950A (zh)
RU (1) RU2407529C2 (zh)
WO (1) WO2006109183A1 (zh)
ZA (1) ZA200708188B (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
IL149352A0 (en) 1999-10-29 2002-11-10 Euro Celtique Sa Controlled release hydrocodone formulations
JP2004512354A (ja) 2000-10-30 2004-04-22 ユーロ−セルティーク，エス．エイ． ヒドロコドン放出制御製剤
US20070190129A1 (en) * 2003-09-02 2007-08-16 Pfizer Inc. Sustained release dosage forms of ziprasidone
US20080305161A1 (en) * 2005-04-13 2008-12-11 Pfizer Inc Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
WO2007027273A1 (en) * 2005-06-20 2007-03-08 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds
CN101242813A (zh) * 2005-06-20 2008-08-13 依兰药物国际有限公司 包含芳基-杂环化合物的毫微粒和控制释放组合物
ES2437331T3 (es) * 2007-07-12 2014-01-10 Janssen R&D Ireland Forma cristalina de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrilo
US9469630B2 (en) 2010-10-18 2016-10-18 Sumitomo Dainippon Pharma Co., Ltd. Sustained-release formulation for injection
RS60651B1 (sr) * 2011-04-15 2020-09-30 Janssen Pharmaceutica Nv Nanosuspenzije leka osušene zamrzavanjem
CN104814926A (zh) * 2015-04-08 2015-08-05 中国药科大学 一种鲁拉西酮纳米混悬剂及其制备方法
EP3352735B1 (en) * 2015-09-21 2023-08-30 Teva Pharmaceuticals International GmbH Sustained release olanzapine formulations
JP2020511483A (ja) 2017-03-20 2020-04-16 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ 徐放性オランザピン製剤
CN109998991A (zh) * 2019-04-28 2019-07-12 中国药科大学 一种盐酸鲁拉西酮长效肌肉注射纳米混悬液及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US6150366A (en) * 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
US6267989B1 (en) * 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
JP2006514923A (ja) * 2002-10-25 2006-05-18 ファイザー・プロダクツ・インク 注射可能な新規なデポ製剤
AU2003300814A1 (en) * 2002-12-04 2004-06-23 Dr. Reddy's Laboratories Inc. Polymorphic forms of ziprasidone and its hydrochloride
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US20070190129A1 (en) * 2003-09-02 2007-08-16 Pfizer Inc. Sustained release dosage forms of ziprasidone

Also Published As

Publication number Publication date
RU2407529C2 (ru) 2010-12-27
US20080193542A1 (en) 2008-08-14
IL186131A0 (en) 2008-01-20
BRPI0609299A2 (pt) 2010-03-23
MX2007012103A (es) 2007-11-20
AU2010201801A1 (en) 2010-05-27
RU2007137846A (ru) 2009-06-20
AU2006233345A1 (en) 2006-10-19
JP2008538751A (ja) 2008-11-06
CN101166514A (zh) 2008-04-23
NZ561950A (en) 2010-09-30
KR20070119678A (ko) 2007-12-20
WO2006109183A1 (en) 2006-10-19
CA2605153A1 (en) 2006-10-19
EP1874268A1 (en) 2008-01-09

Similar Documents

Publication Publication Date Title
ZA200708188B (en) Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
HUS2200028I1 (hu) Immunogén készítmények stabilizálására és kicsapódásuk gátlására szolgáló kiszerelések
HUS1700033I1 (hu) Illékony alkilezõszerek stabilizált készítményei és eljárások azok alkalmazására
ZA200707440B (en) Compositions and methods of making sustained release liquid formulations
EP1883406A4 (en) COMPOSITIONS AND METHOD FOR CONTINUOUS RELEASE OF BETA-ALLANINE
ZA200708260B (en) Nanoparticulate and controlled release compositions comprising cyclosporine
IL183843A (en) Composition of microscopic particles and methods for synthesizing them
ZA200707610B (en) Aerosol and injectable formulations of nanoparticulate benzodiazepine
IL190885A0 (en) Immunogenic compositions and methods of use
HK1125044A1 (en) Methods and compositions for administration of iron
ZA200711068B (en) Injectable compositions and process for preparation of such compositions
ZA200807398B (en) Compositions and methods for enhancing the antioxidant status of animals
ZA200803283B (en) Pharmaceutical gallium compositions and methods
EP1768685A4 (en) COSMETIC COMPOSITIONS COMPRISING RHODIOLA ROSEA AND METHODS THEREOF
ZA200810162B (en) Phenylphrine pulsed release formulations and pharmaceutical compositions
EP1898956A4 (en) ANTITUMORAL COMPOSITIONS AND METHOD
GB0722530D0 (en) Extended release compositions and methods for their manufacture 853
ZA200806601B (en) Cryoprotective compositions and methods of using same
IL192588A0 (en) Cryoprotective compositions and methods of using same
LT1973549T (lt) Būdai ir kompozicijos, skirti geležies įvedimui